’Prevention of infections among people who inject drugs is achievable and effective – if it is properly executed’, stresses ECDC Director Marc Sprenger.
In a joint seminar by Directorate General for Health and Consumer Affairs (DG SANCO), European Food Safety Authority (EFSA) and ECDC at the European Parliament, Marc Sprenger highlighted the decrease of Salmonella infections in EU.
The seminar addressed issues such as the human cost of zoonoses, trends in food-borne diseases, challenges and lessons learnt from epidemiological investigations on the 2011 E.coli outbreak and salmonella controls.
The authors describe the epidemiology of invasive Hib and nontype b H. influenzae infections in children <15 years of age in the United Kingdom from 1994 until 2008, and show that the resurgence in Hib disease during the years 1999-2003 did not affect the epidemiology of invasive nontype b H. influenzae disease in children, which provides further support against serotype replacement.
The second ECDC advisory group meeting will discuss progress and future challenges in reporting and monitoring following the commitment outlined in the Dublin Declaration.
The authors present an appraisal of the pneumococcal epidemiological situation in 11 Central European countries. Data are based on study findings presented at the 12th Central European Vaccine Advisory Group (CEVAG) meeting, held on 21–22 May 2010 in Sofia, Bulgaria, and a literature review of the PubMed database.
On 9 June, ECDC will be hosting a technical side-event to the United Nations High-Level Meeting on AIDS 2011. The event will highlight how countries and regions with differing epidemiology could improve their responses to HIV/AIDS.
In recent years there have been a series of arguments and findings suggesting that Statins (HMG-CoA reductase inhibitors) which used widely to lower cholesterol levels may also be important in reducing the risk associated with severe infective conditions.
The heptavalent pneumococcal conjugate vaccine (PCV7) targets seven of the more than 92 pneumococcal serotypes. Concerns have been raised that non-vaccine serotypes (NVTs) could increase in prevalence and reduce the benefits of vaccination. Indeed, among asymptomatic carriers, the prevalence of NVTs has increased substantially, and consequently, there has been little or no net change in the bacterial carriage prevalence.